drugset / Trial / NCT05459649

Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia

NCT05459649

Phase 2 Unknown 253 enrolled Peking University People's Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Randomized, open-label, multicenter study to compare the efficacy and safety of cyclosporin plus standard steroid compared to standard steroid monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).

Timeline

Start
2022-07-20
Primary completion
2024-07-20
Completion
2025-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 2.5 mg/kg Oral
Subject Prednisone Other / unclassified 40 mg Oral